Fiore Rx Antifungal Nail Lacquer Claims Clipped At NAD After Avoiding FTC
This article was originally published in The Rose Sheet
Executive Summary
NAD welcomes Fiore RX back to the self-regulatory process one year after referring its Fiore Rx Antifungal Nail Lacquer claims to FTC due to the company’s unresponsiveness. The review does not go favorably for the firm, which must discontinue or modify all 22 claims targeted by NAD in its inquiry for lack of substantiating evidence.
You may also be interested in...
Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.